Phytotherapy Research,
Год журнала:
2024,
Номер
38(5), С. 2276 - 2302
Опубликована: Фев. 29, 2024
Abstract
Saffron
(
Crocus
sativus
),
as
an
herbal
medicine,
has
been
extensively
investigated
for
treating
neurological
and
psychiatric
disorders.
This
systematic
review
aimed
to
assess
the
overall
effects
of
saffron
on
cognition,
depression,
anxiety,
sleep
disorders,
attention‐deficit/hyperactivity
disorder
(ADHD),
obsessive–compulsive
(OCD).
Relevant
randomized
controlled
trials
(RCTs)
were
identified
by
searching
PubMed/Medline,
Web
Science,
Clinical
Trials
databases
up
June
2023
according
search
terms
inclusion
criteria.
The
participants
either
healthy
or
suffering
from
some
diseases,
including
consumed
its
extracts
intervention.
risk
bias
was
assessed
Cochrane
guidelines,
PRISMA
statement
followed.
meta‐analysis
performed
using
RevMan
STATA
software.
A
random‐effects
fixed‐effects
model
used
calculate
pooled
effect
sizes.
Forty‐six
RCTs
enrolled,
duration
these
ranged
4
48
weeks
with
extracts,
both
alone
in
combination
conventional
drugs.
more
effective
than
placebo
improving
depression
size
−4.26
(95%
CI:
−5.76,
−2.77),
anxiety
−3.75
−5.83,
−1.67),
disorders
−1.91
−2.88,
−0.93).
non‐inferior
drugs
cognitive
ADHD,
OCD,
it
exhibited
good
tolerance
few
side
effects.
may
exert
protective
roles
represents
a
relatively
favorable
safe
treatment.
Journal of Ethnopharmacology,
Год журнала:
2024,
Номер
330, С. 118180 - 118180
Опубликована: Апрель 16, 2024
Aromatherapy,
a
holistic
healing
practice
utilizing
the
aromatic
essences
of
plant-derived
essential
oils,
has
gained
significant
attention
for
its
therapeutic
potential
in
promoting
overall
well-being.
Use
phytoconstituent
based
oil
played
role
evolving
avenue
aromatherapy
as
complementary
system
medicine.
Pharmacological Research,
Год журнала:
2024,
Номер
201, С. 107090 - 107090
Опубликована: Фев. 2, 2024
Depression
is
a
major
global
health
issue
that
urgently
requires
innovative
and
precise
treatment
options.
In
this
context,
saikosaponin
has
emerged
as
promising
candidate,
offering
variety
of
therapeutic
benefits
may
be
effective
in
combating
depression.
This
review
delves
into
the
multifaceted
potential
saikosaponins
alleviating
depressive
symptoms.
We
summarized
effects
on
structural
functional
neuroplasticity,
elaborated
regulatory
mechanism
modulating
key
factors
affect
such
inflammation,
hypothalamic-pituitary-adrenal
(HPA)
axis,
oxidative
stress,
brain-gut
axis.
Moreover,
paper
highlights
existing
gaps
current
researches
outlines
directions
for
future
studies.
A
detailed
plan
provided
clinical
application
saikosaponins,
advocating
more
targeted
to
speed
up
its
transition
from
preclinical
trials
practice.
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Март 5, 2024
Background:
Alchornea
laxiflora
(Benth.)
Pax
&
K.
Hoffm.
(A.
laxiflora)
has
been
indicated
in
traditional
medicine
to
treat
depression.
However,
scientific
rationalization
is
still
lacking.
Hence,
this
study
aimed
investigate
the
antidepressant
potential
of
A.
using
network
pharmacology
and
molecular
docking
analysis.
Materials
methods:
The
active
compounds
targets
depression-related
were
retrieved
from
public
databases,
such
as
PubMed,
PubChem,
DisGeNET,
GeneCards,
OMIM,
SwissTargetprediction,
BindingDB,
STRING,
DAVID.
Essential
bioactive
compounds,
targets,
signaling
pathways
predicted
silico
analysis,
including
BA-TAR,
PPI,
BA-TAR-PATH
construction,
GO
KEGG
pathway
enrichment
Later
on,
with
interaction
essential
core
depression
verified.
Results:
approach
identified
15
a
total
219
compound-related
14,574
200
intersecting
between
them.
SRC,
EGFR,
PIK3R1,
AKT1,
MAPK1
whereas
3-acetyloleanolic
acid
3-acetylursolic
most
anti-depressant
potential.
functional
analysis
revealed
129
terms,
82
biological
processes,
14
cellular
components,
34
function
terms.
yielded
significantly
enriched
108
pathways.
Out
them,
PI3K-Akt
MAPK
might
have
key
role
treating
Molecular
results
exhibited
that
depression,
MAPK1,
bind
stably
analyzed
laxiflora.
Conclusion:
present
elucidates
pertinent
mechanism
action
.
exert
an
effect
by
regulating
further
investigations
are
required
validate.
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Май 23, 2024
Introduction:
The
prevalence
of
major
depressive
disorder
(MDD)
has
gradually
increased
and
attracted
widespread
attention.
aim
this
study
was
to
investigate
the
effect
a
probiotic
compound
consisting
Bacillus
coagulans
Clostridium
butyricum
,
on
mouse
depression
model.
Methods:
Mice
were
subjected
chronic
unpredictable
mild
stress
(CUMS)
then
treated
with
probiotics
at
different
concentrations.
And
mice
received
behavior
test
such
as
forced
swimming
tail
suspension
test.
After
that,
all
sacrificed
samples
collected
for
analysis.
Moreover,
prefrontal
cortex
(PFC)
gene
expression
gut
microbiota
among
groups
also
analyzed.
Results:
Probiotics
improved
depressive-like
in
CUMS
mice,
indicated
by
decreased
immobility
time
(
p
<
0.05)
intervention
level
5-hydroxytryptamine
(5-HT)
adrenocorticotropic
hormone
(ACTH)
serum.
In
addition,
comparing
PFC
groups,
we
found
that
genes
upregulated
enriched
PI3K-Akt
signaling
pathway
cortex.
downregulated
group
Sfrp5
Angpt2
which
correlated
depression,
reversed
probiotics.
Furthermore,
altered
structure
microbiota,
reduction
cob(II)yrinate
a,c-diamide
biosynthesis
I
group.
Several
species
like
Bacteroides
caecimuris
Parabacteroides
distasoni,
whose
abundance
significantly
but
after
intervention,
showed
positive
correlation
associated
Tbxas1
Cldn2
.
Discussion:
These
findings
suggested
CUMS-induced
depression-like
can
be
alleviated
probiotics,
possibly
through
alterations
microbiota.
